The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A first-in-human dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of oral 2-hydroxyoleic acid (2-OHOA) in adult patients (pt) with advanced solid tumors including grade III/IV glioblastoma multiforme (GBM).
 
Desamparados Roda
No Relationships to Disclose
 
Yvette Drew
No Relationships to Disclose
 
Analia Azaro
No Relationships to Disclose
 
Alan David Smith
No Relationships to Disclose
 
Alastair Greystoke
No Relationships to Disclose
 
Elisabet Sicart
No Relationships to Disclose
 
Pablo V. Escriba
Employment - Lipopharma
Honoraria - Lipopharma
Consulting or Advisory Role - Lipopharma
Travel, Accommodations, Expenses - Lipopharma
 
Xavier Busquets
No Relationships to Disclose
 
Victoria LLado
No Relationships to Disclose
 
Vicente Tur
Employment - Lipopharma
Leadership - Lipopharma
Stock and Other Ownership Interests - Lipopharma
Honoraria - Lipopharma
 
Edwin Klumper
Employment - SMS Oncology
Leadership - SMS Oncology
Stock and Other Ownership Interests - SMS Oncology
Consulting or Advisory Role - Johnson & Johnson
Patents, Royalties, Other Intellectual Property - Chamaeleo Pharma
 
Jordi Rodon Ahnert
No Relationships to Disclose
 
L Rhoda Molife
Research Funding - Lipopharma (Inst)
 
Ruth Plummer
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Biomarin; Clovis Oncology; GlaxoSmithKline; MSD Oncology; Roche/Genentech; Tesaro; Vertex
Research Funding - AstraZeneca/MedImmune (Inst); Clovis Oncology (Inst); e-Therapeutics (Inst); Eisai (Inst); Ipsen (Inst); Vertex (Inst)
Patents, Royalties, Other Intellectual Property - Named on patent of use of PARP inhibitor rucaparib (Inst)
Travel, Accommodations, Expenses - MSD Oncology; Roche/Genentech